Overview
Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management
Status:
Completed
Completed
Trial end date:
2016-03-01
2016-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to compare two medications currently injected intra-operatively to help decrease pain after surgery in patients undergoing a primary total hip replacement (THR). The two medications are Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine versus bupivacaine with epinephrine. This study is looking to see if one medication works better than the other in managing post-operative pain after THR. The study hypothesis is that Exparel® plus bupivacaine with epinephrine will demonstrate better pain management in THR patients post-operatively. Both medications are FDA-approved for post-operative analgesia.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
American Hip InstituteTreatments:
Bupivacaine
Epinephrine
Epinephryl borate
Racepinephrine
Criteria
Inclusion Criteria:- Patients scheduled to undergo primary unilateral total hip replacement
- Patients diagnosed with hip osteoarthritis
- Patients failed to improve with conservative measures
- Patients willing and able to sign informed consent
Exclusion Criteria:
- Revision total hip replacement
- Bilateral total hip replacement
- Birmingham hip resurfacing
- Patients with hepatic/kidney disease
- Patients with a known allergy to bupivacaine or other local anesthetics